Atrial Fibrillation Market To Reach $3,370.70 Million By 2030 With A CAGR Of 6.4% From 2021: Allied Market Research


(MENAFN- EIN Presswire)

Atrial Fibrillation

PORTLAND, OREGON, UNITED STATES, May 5, 2023 /einpresswire.com / -- Atrial fibrillation, a type of irregular heartbeat, affects millions of people worldwide and can lead to serious health complications if left untreated. As such, the market for atrial fibrillation treatment options has been growing steadily in recent years.

According to Allied market research, the atrial fibrillation market size was valued at $1,825.85 million in 2020. This represents a significant increase from previous years, and the market is projected to continue growing at a compound annual growth rate (CAGR) of 6.4% from 2021 to 2030. By the end of the decade, the market is expected to reach $3,370.70 million.

Several factors are driving this growth, including an aging population, increased awareness of atrial fibrillation as a health concern, and advances in medical technology. In particular, there has been a rise in the use of minimally invasive procedures and catheter ablation for the treatment of atrial fibrillation, which is expected to further fuel market growth.

However, the atrial fibrillation market also faces challenges such as high costs associated with treatment options and a lack of awareness and access to treatment options in certain regions. Nonetheless, with ongoing research and development efforts and the continued demand for effective atrial fibrillation treatments, the market is poised for continued growth in the years to come.

Download PDF Brochure at:

Key Market Players

1.Johnson & Johnson
2.MicroPort Scientific
3.Boston Scientific
4.st. jude medical
5.Medtronic plc
6.Abbott Laboratories
7.Biotronik SE & Co. KG
8.Koninklijke Philips N.V.
9.Siemens AG
10.AtriCure

Let's take a closer look at the different segments of the atrial fibrillation market:

By Type:
The atrial fibrillation market can be segmented into surgical and non-surgical treatments. Surgical treatments involve more invasive procedures such as catheter ablation or open-heart surgery, while non-surgical treatments include medications and lifestyle changes. The non-surgical segment is expected to have a higher growth rate due to the growing popularity of non-invasive treatments for atrial fibrillation.

By Technology:
The market for atrial fibrillation treatment technologies includes radiofrequency, laser, cryotherapy, and others. Radiofrequency ablation is the most widely used technology, accounting for the largest market share due to its high success rate and lower complication rates.

By End User:
The atrial fibrillation market can also be segmented by end-user, with hospitals and specialty clinics accounting for the largest market share. This is due to the fact that atrial fibrillation is often diagnosed and treated in hospitals and specialized clinics. However, there is also a growing trend towards outpatient procedures, which could lead to an increase in demand for atrial fibrillation treatments in other settings such as ambulatory surgical centers.

Inquire Before Buying:

The atrial fibrillation market can also be segmented by region, with North America, Europe, Asia-Pacific, and LAMEA being the four main regions. Let's take a closer look at each region:

North America:
North America is expected to have the largest share of the atrial fibrillation market due to the high prevalence of atrial fibrillation in the United States and Canada, as well as the presence of key market players in the region. Additionally, the region has a well-established healthcare system and high levels of healthcare expenditure, which contribute to the growth of the market.

Europe:
Europe is the second-largest market for atrial fibrillation treatments, with Germany, France, the UK, and Italy being the major markets in the region. The increasing prevalence of atrial fibrillation in Europe, along with a growing elderly population, is driving the growth of the market. Moreover, the presence of leading medical device manufacturers in Europe is boosting market growth.

Asia-Pacific:
The Asia-Pacific region is expected to have the fastest growth rate in the atrial fibrillation market due to the rising prevalence of atrial fibrillation, particularly in countries such as China, India, and Japan. The region also has a large and aging population, which is contributing to the growth of the market. Furthermore, the increasing adoption of advanced medical technologies and the presence of a large number of medical device manufacturers in the region are driving market growth.

LAMEA:
The LAMEA region is the smallest market for atrial fibrillation treatments, with Latin America, the Middle East, and Africa being the main regions. The market in this region is expected to grow at a slower rate than other regions due to the limited healthcare infrastructure and a lack of awareness about atrial fibrillation. However, increasing healthcare expenditure and rising awareness about the condition are expected to contribute to the growth of the market in the region.

PURCHASE FULL REPORT:

David Correa
Allied Analytics LLP
+1-800-792-5285
email us here

MENAFN05052023003118003196ID1106186198


EIN Presswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.